Indication
Bronchogenic
8 clinical trials
14 products
6 drugs
Product
CarboplatinClinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsStatus: Active (not recruiting), Estimated PCD: 2024-08-23
Product
PemetrexedProduct
BLU-451Clinical trial
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
osimertinibProduct
BLU-945Product
PralsetinibClinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-21
Clinical trial
An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2020-08-20
Product
SHR-1210Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung CancerStatus: Terminated, Estimated PCD: 2022-12-09
Product
carboplatinProduct
pemetrexedProduct
BLU-701Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsStatus: Terminated, Estimated PCD: 2022-05-16
Product
AlectinibClinical trial
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Drug
PralsetinibDrug
CisplatinProduct
PembrolizumabDrug
GemcitabineDrug
TiragolumabDrug
Nab-PaclitaxelClinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-06-30
Drug
AdebrelimabProduct
Carboplatin/CisplatinProduct
Etoposide